ASP-7317 is under clinical development by Astellas Pharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ASP-7317’s likelihood of approval (LoA) and phase transition for Dry (Atrophic) Macular Degeneration took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 08 May 2021 increased ASP-7317’s Phase Transition Success Rate (PTSR) for Juvenile Macular Degeneration (Stargardt Disease).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ASP-7317 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ASP-7317 overview

ASP-7317 (Retinal pigment epithelial cell program, MA09-hRPE) is under development for the treatment of Stargardt disease (juvenile macular degeneration) and geographic atrophy associated with dry age-related macular degeneration (dry AMD). RPE cells are administered as subretinal injections. Retinal pigment epithelial cells are derived from human embryonic stem cells (hESCs). The program is based on advanced cell technology. It was also under development for the treatment of myopic macular degeneration.

Astellas Pharma overview

Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Quick View ASP-7317 LOA Data

Report Segments
  • Innovator
Drug Name
  • ASP-7317
Administration Pathway
  • Intraocular
Therapeutic Areas
  • Ophthalmology
Key Developers
  • Sponsor Company: Astellas Pharma
  • Originator: Astellas Institute for Regenerative Medicine
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.